The rationale for re-administration of genetically engineered biological drugs in patients with COVID-19


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

Currently, there are no evidence-based data to recommend the use of repeated doses of interleukin-6 (IL-6) blockers for the treatment of patients with COVID-19. To date, the data on the effectiveness of IL-6 blockers are contradictory. The use of drugs of this group can increase the risk of suppression of the immune system with a decrease in resistance to infectious agents.

Texto integral

Acesso é fechado

Sobre autores

I. Burashnikova

Kazan State Medical Academy - Branch Campus of the Russian Medical Academy of Continuous Professional Education

Kazan, Russia

Bibliografia

  1. Zhang Q, Bastard P., Liu Z. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. 2020;370(6515):eabd4570. doi: 10.1126/SCIENCE.ABD4570.
  2. Bastard P., Rosen L.B., Zhang Q. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;370(6515):eabd4585. doi: 10.1126/SCIENCE.ABD4585.
  3. Xu Z., Shi L., Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet. Resp Med. 2020;8(4):420-422. doi.org/10.1016/S2213-2600(20)30076-X
  4. Trouillet-Assant S., Viel S., Gaymard A., et al. COVID HCL Study group. Type I IFN immunoprofiling in COVID-19 patients. J Allergy Clin Immunol. 2020;146(1):206-8.e2. Doi: 10.1016/j. jaci.2020.04.029.
  5. The COVID-19 Host Genetics Initiative, a global initiative to elucidate the role of host genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic. COVID-19 Host Genetics Initiative. Eur J Hum Genet. 2020;28(6):715-18. doi: 10.1038/s41431-020-0636-6.
  6. Huang C, Wang Y, Li X., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5.
  7. Jakhmola S, Indari O, Chatterjee S, Jha HC. SARS-CoV-2, an Underestimated Pathogen of the Nervous System. SN Compr Clin Med. 2020 Sep 28:1-10. doi: 10.1007/s42399-020-00522-7. Epub ahead of print. PMID: 33015550; PMCID: PMC7520376.
  8. Del Valle D.M., Kim-Schulze S., Huang H.H., et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med. 2020;26(10):1636-43. doi: 10.1038/s41591-020-1051-9.
  9. Laing A.G., Lorenc A., Del Molino Del Barrio I., et al. A dynamic COVID-19 immune signature includes associations with poor prognosis. Nat Med. 2020;26(10):1623-35. Doi: 10.1038/ s41591-020-1038-6.
  10. Hyder Pottoo F., Abu-Izneid T, Mohammad Ibrahim A., et al. Immune system response during viral Infections: Immunomodulators, cytokine storm (CS) and Immunotherapeutics in COVID-19. Saudi Pharm J. 2021;29(2):173-87. Doi: 10.1016/j. jsps.2020.12.018.
  11. Liuzzo G, Patrono C. COVID 19: in the eye of the cytokine storm. Eur Heart J. 2021;42(2):150-51. doi: 10.1093/eurheartj/ehaa1005.
  12. Feldmann M., Maini R.N., Woody J.N., et al. Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed. Lancet. 395(10234):1407-409. Doi: 10.1016/ S0140-6736(20)30858-8.
  13. Йокота Ш., Куройва Е., Нишиока К. Новая коронавирусная болезнь (COVID-19) и «цитокиновый шторм». Перспективы эффективного лечения с точки зрения патофизиологии воспалительного процесса. Инфекционные болезни: новости, мнения, обучение. 2020;9(4):1325
  14. Профилактика, диагностика и лечение новой коронавирусной инфекции COVID-19. Версия 11 (07.05.2021)
  15. https://app.magicapp.org/ff/guideline/L4Q5An/ rec/Lq4Y0j
  16. Khani E., Khiali S., Entezari-Maleki T. Potential COVID-19 Therapeutic Agents and Vaccines: An Evidence-Based Review. J Clin Pharmacol. 2021;61(4):429-60. doi: 10.1002/jcph.1822.
  17. Siemieniuk R.A., Bartoszko J.J., Ge L., et al. Drug treatments for COVID-19: living systematic review and network meta-analysis. BMJ. 2020;370:m2980. doi: 10.1136/bmj.m2980.
  18. Клинический протокол лечения больных новой коронавирусной инфекцией COVID-19, находящихся на стационарном лечении в медицинских организациях государственной системы здравоохранения города Москвы. 2020.
  19. URL: https://COVID19evidence.net.au/ffliving-guidelines
  20. URL: https://app.magicapp.org/ff/guideline/ L4Q5An/rec/jMxdW
  21. URL: https://rsmu.ru/fileadmin/templates/DOC/ Faculties/LF/gt2/COVID-19/Ispanskii_protokol_ klinicheskogo_vedenija_pacientov_s_COVID-19. pdf (первоисточник не найден/original source not found).
  22. Xu X., Han M., Li T., et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci USA. 2020;117(20):10970-75. doi: 10.1073/pnas.2005615117.
  23. Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (7th Interim Edition). China NHCOTPSRO. URL: http://www.nhc.gov.cn/ yzygj/s7653p/202003/46c9294a7dfe4cef80dc 7f5912eb1989/files/ce3e6945832a438eaae41 5350a8ce964.pdf
  24. Luo P., Liu Y, Qiu L., et al. Tocilizumab treatment in COVID-19: A single center experience. J Med Virol. 2020;92(7):814-18. doi: 10.1002/jmv.25801.
  25. Zhang, X., et al., First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab. Blood Adv. 2020;4(7):1307-10. doi: 10.1182/bloodadvances.2020001907.
  26. Pilot, Randomized, Multicenter, Open-label Clinical Trial of the Use of Tocilizumab for Treatment of SARS-CoV-2 Infection (COVID-19). URL: https:// clinicaltrials.gov/ct2/show/study/NCT04332094
  27. Rosas I.O., Bru N., Waters M., et al. Tocilizumab in Hospitalized Patients with Severe COVID-19 Pneumonia. N EnglJ Med. 2021:NEJMoa2028700. doi: 10.1056/NEJMoa2028700.
  28. Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019-A Multicenter, Randomized and Controlled Clinical Trial Study. URL:https://clinicaltrials.gov/ct2/ show/NCT04310228?term=NCT04310228&dra w=2&rank=1.
  29. Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients -Tocilizumab Trial - CORIMUNO-19 - TOCI (CORIMUNO-TOCI). URL: https://clinicaltrials. gov/ct2/show/results/NCT04331808?term=NCT 04331808&draw=2&rank=1&view=results
  30. Hermine O., Mariette X., Tharaux PL., et al. CORIMUNO-19 Collaborative Group. Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial. JAMA. Intern. Med. 2021;181(1):32-40. Doi: 10.1001/ jamainternmed.2020.6820. Erratum in: JAMA Intern Med. 2021;181(1):144.
  31. RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 20211;397(10285):1637-doi: 10.1016/S0140-6736(21)00676-0.
  32. Gordon A.C., Mouncey P.R., Al-Beidh F., et al. Interleukin-6 Receptor Antagonists in Critically Ill Patients with COVID-19 - Preliminary report The REMAP-CAP Investigators. medRxiv. 2021.01.07.21249390. doi: 10.1101/2021.01.07.21249390.
  33. URL:https://grls.rosminzdrav.ru/Grls_View_ v2.aspx?routingGuid=4ebb0265-ade9-41c5-b63c-e37936eacc8b&t=

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bionika Media, 2021

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies